Published August 2007 | Version v1
Miscellaneous

Development of 188Re-Hynic-Lanreotide as radiopharmaceutical for cancer treatment

Description

Full text: Hynic ligand, which complexes with metal radionuclide in milder condition than other normal ligands, was conjugated with peptide, Lanreotide. The conjugated product was purified by HPLC and its concentration was estimated by UV-Vis spectrophotometer. Molecular weight of Hynic-Lanreotide was confirmed by mass spectrometer (TOF-MS) with M/Z at 1231. Labeling of Hynic-Lanreotide with Re-188 radionuclide was done by wet labeling to verify optimum condition. The optimum condition found was as follows; 20 mg coligand (tricine), 350 ?g reducing agent (SnCl2.2H2O) and 10 ?g Hynic-Lanreotide labeled with 3-10 mCi ReO-4 at 70 OC for 1 hour. The labeling yield was ranged between 60 and 70%. Further purification by solid phase extraction (C-18 sep pak?) increased radiochemical purity to 85-90%

Availability note (English)

Available in abstract form only, full text entered in this record. Available from Thailand Institute of Nuclear Technology, Bangkok (Thailand)

Additional details

Publishing Information

Imprint Pagination
11 p.
Report number
INIS-TH--173

Conference

Title
10. Conference on Nuclear Science and Technology
Dates
16-17 Aug 2007
Place
Bangkok (Thailand)

Optional Information

Secondary number(s)
NST--10-MS05